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Abstract
Transdermal buprenorphine is a new formulation of the old drug available for the treatment of cancer and 
non-cancer pain. The drug offers number of interesting new features and was found effective in clinical trials in 
cancer patients with pain. We performed a survey of the use of buprenorphine patches for one year. In the 
survey we included 58 admitted patients (67 admission periods), whose clinical records and drug charts were 
subjected to analysis. Opioid naive patients were started either on 5 or 10 μg/hour. Mean buprenorphine dose 
was 22.3 μg/hour (95% CI: 16–28.6), increased on day 8 to 25.4 μg/hour (95% CI: 18.6–32) and ended up at the 
dose of 31.3 μg/hour (95% CI: 20.9–41.6) on the last day of treatment; day 19 (95% CI: 14.5–23.5). The overall 
dose increase was approximately 2% per day. Approximately half of the patients needed beside buprenorphine 
other opioids either in a slow release or immediate release form, usually morphine or oxycodone. Swapping from 
morphine, oxycodone and fentanyl to buprenorphine was without problems in all of the cases. The doses of 
all opioids administered calculated as oral morphine equivalents showed insignificant decreases for morphine 
and oxycodone to buprenorphine swaps. In case of fentanyl the oral morphine equivalents of opioids were 
significantly lower after swap (p = 0.0039). No signs of antagonism between the drugs were observed. In 
conclusion: buprenorphine patches appear to be useful in the treatment of cancer pain, either as monotherapy 
or in combination with other opioids. Swap from fentanyl to buprenorphine offers perspective of achievement 
of pain control with much less toxicity and should be investigated in more detail.
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Introduction
Opioids remain the mainstay of the treatment in 
cancer pain [1, 2]. There are many opioids available 
on the market and it is unclear which one should 
be used when. It is also impossible to say which 
opioid is better than the other and the choices are 
made randomly basing on their availability, price and 
the patient friendliness. Biased articles, not based 
on any experience, commissioned by the pharma-
ceutical industry have potentially high impact on 
prescribing [3]. The simple notion that pure or full 
μ-opioid-receptor agonists are better than partial 
agonist was never proven in clinical trials and bu-
prenorphine was underused for many decades. 
Buprenorphine sublingual tablets are known 
in pain control for several decades [4]. The drug 
was found effective in cancer pain in settings rel-
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evant to palliative care [4–10]. Newly formulated 
transdermal buprenorphine patches was reintro-
duced recently and apparently possess some inter-
esting features which may be used to the benefit of 
patients with pain. The data on the use of this new 
formulation are still limited. There is not much ex-
perience in switching to buprenorphine from other 
opioids and this stimulated us to perform this sur-
vey. Also, it was important to observe how much of 
the other opioids need to be given together with 
buprenorphine to obtain optimal effect. 
Material and methods
Drug charts were analysed retrospectively from 
01.04.2009 until 01.04.2010. All patients with com-
pleted admission resulting either in discharge or 
death were included into survey. Patients treated in 
the out-patient clinic were excluded from this survey 
as exact data on the use of breakthrough medication 
was usually missing. Some patients were admitted 
more than once and the separate admissions of 
the same patients were included in some analyses. 
Patients were admitted to the ward and their pain 
was assessed. When the pain was inadequately 
controlled and/or the therapy with opioids caused 
unacceptable adverse effects, the patients were 
swapped from the original opioid to buprenorphine. 
For calculation of the doses of opioids opioid calcula-
tor was used from the website: http://book.pallcare.
info/index.php?op=plugin&src=opiconv. The initial 
dose of buprenorphine when swapped from fen-
tanyl was decreased by 50% in comparison to the 
calculated dose (μg/μg). The doses of buprenorphine 
were adjusted after one week in order to obtain 
optimal results. For the analysis, usually the dose 
of drugs on day 8 was taken for analysis, as well 
as the last full day of treatment before either death 
or discharge. For analysis all opioids were converted 
into oral morphine equivalents (OME) per 24 hours. 
Dose increments of buprenorphine were calculated 
as percentage of the original dose per day. Prob-
ability was calculated with the Wilcoxon exact test 
and values of p < 0.05 were considered significant.
Results
Patient’s demographics
In the period of 12 months 289 new patients were 
admitted to the Dove House Hospice. Fifty eight new 
patients (20%) were prescribed buprenorphine. Six 
patients were admitted more than once, hence 9 
admission periods were added to the survey, making 
total numbers of admission periods equal 67. Forty 
seven (81%) patients prescribed buprenorphine were 
suffering from cancer, of which 14 (30%) was lung 
cancer. The mean age of all patients was 67 (95% CI: 
45–84). There were 36 women (62%) and 22 men 
(38%). Mean admission duration was 18 (95% CI: 
14.9–21.2) days while mean number of days when 
patients were treated with buprenorphine was 15.8 
(95% CI: 12.7–18.8). Some patients were started on 
buprenorphine after a couple of days of observation. 
Total number of treatment days was 1071. Forty two 
treatment periods (62%) ended up with discharge, 24 
(35%) with patient’s death and in 2 cases (3%) the 
treatment was discontinued because of adverse effects.
Starting dose of buprenorphine and dose 
increments
Eleven patients who were opioid naive started on 
5 μg/hour (9 patients) and 10 μg/hour (2 patients). In 
this group the initial dose remained the same until 
the end of the observation period suggesting good 
pain control. In this group only occasionally other 
opioids were used. In 36 patients buprenorphine 
was initiated by us and the duration of this admission 
period was longer than 7 days. Shorter admission 
periods were not analysed. In these 36 patients mean 
initial dose of buprenorphine was 22.3 (95% CI: 
16–28.6) μg/hour and increased on day 8 to 25.4 
(95% CI: 18.6–32) μg/hour and ended up at the dose 
of 31.3 (95% CI: 20.9–41.6) μg/hour on the last day 
19 (95% CI: 14.5–23.5). The overall calculated dose 
increase was approximately 2% per day. There was no 
significant difference in dose increase percentage 
between the titration phase (day 1–7) and the fol-
lowing treatment days.  
Time to the optimal dose
Time to establish the optimal dose was estimated 
in 47 patients who started with buprenorphine during 
the first admission. In 25 patients (53.2%) the initial 
dose was immediately the optimal dose and was not 
adjusted during the rest of the treatment period. 
In 11 patients (23.4%) the optimal dose was estab-
lished within 8 days and continued thereafter, in 5 
patients (10.6%) the optimal dose was established 
between 7–14 days and in 6 patients (12.8%) cas-
es the dose was established in more than 15 days or 
could not be established at all and was still rising. 
This included patients whose dose of buprenorphine 
increased in the last week of life. It is probable that 
many patients with rising doses of buprenorphine and 
other opioids at the end of their lives had increase 
of pain intensity and/or developed opioid tolerance. 
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Swapping to buprenorphine 
From 49 patients initiated by us on buprenor-
phine, 11 (22.4%) were previously opioid naive, 10 
(20.4%) were on oxycodone, 12 (24.5%) were on 
morphine sulphate, 4 (8.2%) on fentanyl, 4 (8.2%) 
on morphine and fentanyl, 2 (4%) on oxycodone and 
fentanyl, 2(4%) on morphine, s.c. diamorphine and 
fentanyl, 1 (2%) on morphine and s.c. diamorphine 
and 3 (6%) on codeine. 
Swapping to buprenorphine from oxycodone 
and morphine
Ten patients were swapped from oxycodone to 
buprenorphine (Figure 1). In most cases because of 
insufficient pain control. The dose of oxycodone (in 
OME) prior to swap was 177.5 mg/24 hours (95% 
CI: 23–332). The dose of buprenorphine and oxy-
codone on day 8 was 193.8 mg/24 hours (95% CI: 
21.3–408.8) in OME and at the last day — 20 (95% CI: 
3.9–36) the dose of buprenorphine and oxycodone 
was 140.9 (95% CI: 4–277.8). The differences of the 
means were not statistically significant (p = 0.3)
In 6 cases the swap resulted in final lower doses of 
buprenorphine or no need of other opioid medica-
tion at all. In 4 cases the swap resulted in only mini-
mal or no decrease of the dose and the patients still 
needed considerable doses of other opioids. In none 
of the cases final dose of opioids was higher than 
the original dose before swap.
Twelve patients were swapped from morphine 
sulphate to buprenorphine (Figure 2). The dose of 
morphine prior to swap was 162.7 mg/24 hours (95% 
CI: 4.5–329.9) in OME. On day 8 the dose of buprenor-
phine and morphine was 71.6 mg/24 hours (95% CI: 
20.1–123) and on the last day of the treatment; day 
13 (7.1 to 18.4), the dose of buprenorphine and mor-
phine was 97.5 mg/24 hours (95% CI: 44.1–150.9). 
The differences between these means were not 
statistically significant (p = 0.3). In 8 cases the swap 
resulted in final, much lower doses of buprenor-
phine or no need of other opioid medication at all. 
In 4 cases the swap resulted in only minimal or no 
decrease of the dose and the patients still needed 
considerable doses of other opioids. In none of 
the cases final dose of opioids was higher than the 
original dose before swap.
Swapping to buprenorphine from fentanyl
Twelve patients were swapped from fentanyl 
to buprenorphine (Figure 3). Ten because of in-
Figure 1. Swap of oxycodone to buprenorphine (n 
= 10). On the Y axis, oral morphine equivalents in 
mg/24 h. A — oxycodone dose prior to swap, B — bu-
prenorphine dose on day 8, C — dose of oxycodone 
on day 8 still needed to provide good pain control, 
D — dose buprenorphine on the last day of treat-
ment, which was day 20 (95% CI: 3.9–36), E — dose 
of oxycodone on the last day of treatment still 
needed to control pain. The differences between the 
groups were not significant (p = 0.3)
Figure 2. Swap of morphine sulphate to buprenor-
phine (n = 12). On the Y axis, oral morphine equiva-
lents in mg/24 h. A — morphine dose prior to swap, 
B — buprenorphine dose 8 days after swap, 
C — dose of morphine on day 8 still needed to main-
tain pain control, D — buprenorphine dose at the last 
day of treatment: day 13 (7.1–18.4), E — dose 
of morphine still needed to maintain analgesia. 
The differences between the groups were not signifi-
cant (p = 0.3)
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adequate pain control, two because of adverse 
effects. Only 4 patients were on fentanyl alone. 
Other needed other opioids prior to swap. When 
doses of opioids were converted to OME prior 
to swap, the dose of fentanyl and other opio-
ids was equal to 368.2 mg/24 hours  (95% CI: 
185.8–550.6). On day 8 after swap the dose of 
buprenorphine and other opioids was equal to 
309.9 mg/24 hour (95% CI: 53–566.7). At the 
last day of treatment; day 18 (95% CI: 11–24.1), 
the dose of buprenorphine and other opio-
ids was 196.4 mg/24 hours (95% CI: 60.3–332.6). 
The difference in the doses of opioids between day 
0 and the last day of treatment was statistically 
significant (p = 0.0039).
Figure 3 shows fentanyl and other opioids (in 
OME) on day 0, day 8 of the treatment and on 
the last day of the treatment. While on day 0 the 
dose of fentanyl was high and the dose of other 
opioids low, this changed on day 8. Lower doses of 
buprenorphine were matched by higher doses of 
other opioids. On the last day of treatment the dose 
of buprenorphine remained approximately the same, 
but the dose of other opioids decreased to the level 
comparable to day 0.
Adverse effects
Eight of the 58 (13.8%) patients treated with 
transdermal buprenorphine experienced intolerable 
adverse effects (Table 1). One patient experienced 
hallucinations four days after beginning of the treat-
ment. This prompted us to discontinue buprenor-
phine. One patient was claimed by the family to be 
confused after one day of treatment with 5 μg/hour. 
Family requested to discontinue treatment. One 
patient who was slightly confused was successfully 
treated with haloperidol. For the other seven, the 
symptoms began hours to days after increasing the 
dose and reducing the dose resulted in the symp-
toms settling down and in all cases disappearing. 
Several patients developed skin rash under the patch. 
In no one case this was the reason to discontinue 
treatment. However, data on the skin rash were 
not well reported in the notes. The same is true for 
the constipation. Many patients were constipated 
and were treated with laxatives. This adverse effect 
was never intolerable and did not influence chang-
es of medication. Several patients treated with other 
opioids prior to begin with buprenorphine were 
intolerably constipated and this symptom became 
less pronounced after swapping to buprenorphine. 
No rebound diarrhoea was observed. Unfortunately 
this too was not well reported in the notes and can-
not be analysed here.
Discussion
Transdermal buprenorphine is available since 
short for the treatment of cancer and non-cancer 
pain. It is still not trusted and is grossly underused 
simply because of ill funded notion that pure opioid 
agonists would be better than partial agonists [3]. 
In our hospice we performed a survey of the use of 
this drug and its potential value in cancer pain con-
trol. The value of the data presented by us is limited 
by the retrospective character of our survey, low 
number of patients in each group and impossibility 
to take into account other than opioid treatments like 
Figure 3. Swap of fentanyl to buprenorphine 
(n = 12). On the Y axis, oral morphine equivalents in 
mg/24 h. A — fentanyl dose prior to swap, B — dose 
of other opioids needed to control pain, C — dose of 
buprenorphine on day 8, D — dose of other opioids 
on day 8, E — dose of buprenorphine in the last full 
day of treatment which was day 18 (95% CI: 11–24.1), 
F — dose of other opioids in the last full day 
of treatment. The differences between A and C, A 
and E were statistically significant (p = 0.0039)
Table 1. Adverse effects in patients treated with 
buprenorphine
Adverse effect Number of patients
Confusion 2
Hallucinations 1
Nausea 1
Drowsiness 2
Skin irritation 1
Adhesion problems 1
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use of steroid injections, use of NSAIDs, paracetamol 
and radiotherapy. The survey did not analyse directly 
the pain intensity reported by the patient, but only 
the use of other, usually PRN opioids as a surrogate 
for this. These data are indirect, but still mirror eve-
ryday practice.
Main goal of the survey was to establish safe 
initial doses of buprenorphine patches in old and 
frail terminally ill patients, possible problems of 
combining opioids like morphine and oxycodone, 
the dose of additional opioids needed to obtain an-
algesia, possible antagonisms and the problems with 
switching from one opioid to the other.
Buprenorphine had been well tolerated by most 
of the patient. In many patients the doses of bu-
prenorphine needed to control their pain were lower 
than of the original opioids or opioids combinations, 
which caused that many patients, after 1–2 days of 
treatment were much more alert and active. 
Important finding is the fact that buprenor-
phine was generally used in low or very low doses. 
Especially initial doses of buprenorphine in naive 
patients were 5–10 μg/hour. Median dose of all 
buprenorphine prescribed to our patients was 20 
μg/hour. In several countries, like Poland, buprenor-
phine’s lowest dose is still 35 μg/hour and this patch 
should be changed every 4 days (Transtec®). In prac-
tice Transtec® patches were used only in 1/3 of the 
treatment periods studied by us. In 2/3s of the treat-
ment periods the buprenorphine patches (Butrans®) 
were used in different combinations which should 
be changed once per week. This means that in coun-
tries where the Butrans® patches are still unavailable, 
the adequate treatment may be difficult or impos-
sible. It is not advisable to cut the patches in pieces. 
And in fact in many countries this practice is banned.
The manufacturers’ licence limits the use of the 
buprenorphine patches up to 140 μg/hour. This limi-
tation puts many clinicians off as they think that 
this cap has something to do with the ceiling effect 
[11, 12] may limit their ability to increase the dose 
and finally they would need to swap back to other 
opioids which may then appear to be ineffective. In 
our survey only two patients needed the maximal 
dose of 140 μg/hour toward the end of their life. No 
signs of tolerance development or ceiling effect were 
observed in our patients. None of the patients need-
ed to be swapped back to other opioid. The cap of 
140 μg/hour is dictated probably by the intensity of 
exposure of the skin to the glue. Several patients de-
veloped in our survey a toxic effect to the glue (most 
probably not to the buprenorphine itself). Using high 
doses of patches means larger areas exposed to the 
glue toxicity and shorter rotation time of the site 
before the next patch is being administered. This may 
dramatically increase the frequency of local reactions. 
Beyond this survey, in a patient with osteoporosis, 
with good reaction to 140 μg/hour buprenorphine 
patches for 17 months and severe local reaction, 
we managed to swap the patient to the sublingual 
administration of buprenorphine, as previously all 
known opioids were found to cause unacceptable 
adverse effects.
Interestingly in half of the treatment periods pa-
tients were treated with buprenorphine only, and 
practically did not need any additional opioids, may 
be with the exceptions of the period just before 
death. In another half of the treatment periods, 
buprenorphine needed to be combined with other 
opioids. No signs of antagonism or loss of efficacy 
of the combinations was observed. Instead, in many 
patients, addition of buprenorphine made possible 
to use very low additional doses of other opioids. 
Equal good results were obtained in combination of 
buprenorphine with oxycodone as with morphine. 
The combinations of buprenorphine with fenta-
nyl were avoided. In practice the efficacy of these 
combinations were equal, although not formally 
assessed as the numbers of patients in each group 
were rather small.
Swap from fentanyl to buprenorphine was usually 
done in one or two days and was successful in most 
of the cases. In the literature reported conversion ra-
tio between fentanyl and buprenorphine is supposed 
to be even up to 1:2, fentanyl being twice as strong 
(μg/μg) as buprenorphine. In our clinical practice, 
however, we used a completely different conversion 
ratio 1: 0.5–0.66. After this conversion the pain inten-
sity went up as in the first week witnessed by need 
of increased doses of other opioids. However, the 
dose of other opioids, without increasing the dose 
of buprenorphine patches settled in 1–2 weeks later. 
There were not enough patients in this cohort to say 
whether the conversion ratio was linear at all dose 
levels or not. It is possible that ratios 1:2 and 1:1 cited 
in the literature were derived immediately after con-
version not taking into account long time-to-steady 
state characteristic for buprenorphine. 
It is very difficult to say exactly which doses of 
additional opioids should be chosen to the dose of 
buprenorphine. Our survey did not give answer to 
this question. The doses of other opioids, either im-
mediate or controlled release were in no way propor-
tional to the dose of buprenorphine. So, patients on 
high doses of buprenorphine could still benefit 
from 5 or 10 mg morphine PRN. This was similar 
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for morphine and oxycodone. This is of particular 
interest as oxycodone is seen as not only μ-opioid 
receptor agonist, but also k-opioid-receptor agonist 
[4, 13], while buprenorphine has partial μ-opioid 
receptor agonistic activity and k-opioid receptor 
antagonistic activity [15]. If this k agonistic activity 
was of importance, buprenorphine probably would 
show antagonism with oxycodone. This seems not 
to be the case. 
Swapping from fentanyl to buprenorphine re-
sults in much lower doses of opioids needed to 
control pain. This suggests that fentanyl, at least in 
some cases may exercise a potent hyperlagesic effect 
which is missing in buprenorphine [16, 17]. In many 
cases after swap our patients revived and were not 
only pain free, but also showed much less neurotoxic 
effects (delirium, sleeplessness, confusion). 
Conclusions
Transdermal buprenorphine offers certainly some 
new and attractive features. It is a difficult drug in 
the sense that pharmacological effects related to 
steady state are delayed for 1–2 weeks. Conversion 
ratio from fentanyl to buprenorphine should be cer-
tainly reviewed in the future. Approximately half of 
the patients treated with buprenorphine need other 
opioids, usually morphine or oxycodone. This is ap-
proximately the same as in the case of fentanyl. 
The dose of other opioids used with buprenorphine 
is highly variable and should be titrated starting from 
the very low doses. Buprenorphine is particularly 
interesting in case of inefficacy of fentanyl. However, 
problems with skin toxicity with buprenorphine 
patches are serious and some patients may develop 
skin toxicity and need discontinue therapy.
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